Suven Life Sciences Limited (NSE:SUVEN)

Market Cap	78.95B +83.1%
Revenue (ttm)	189.73M +223.6%
Net Income	-3.82B
EPS	-15.11
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	206,329
Open	281.35
Previous Close	279.95
Day's Range	273.70 - 286.05
52-Week Range	124.11 - 403.35
Beta	0.95
Analysts	n/a
Price Target	n/a
Est. Earnings	Jan 29, 2027

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer’s disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 142
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUVEN

Financial Performance

In fiscal year 2026, Suven Life Sciences's revenue was 71.15 million, an increase of 6.89% compared to the previous year's 66.56 million. Losses were -2.76 billion, 71.9% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error